Women’s health biotech KaNDy dick­er­ing with Al­ler­gan about a $400M buy­out deal — re­port

The lat­est buy­out buzz fo­cus­es on a small UK biotech spin­out work­ing on a new drug for women’s health.

Bloomberg is re­port­ing this morn­ing that Al­ler­gan $AGN is in late-stage talks to buy out KaNDy Ther­a­peu­tics in a deal that could val­ue the com­pa­ny at up to $400 mil­lion.

De­tails are few and far be­tween, but the com­pa­ny has a po­ten­tial hor­mone re­place­ment ther­a­py called NT-814 that would fit the pro­file for Al­ler­gan’s BD team.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER